Loading...
Loading...
RPTX| Name | Value |
|---|---|
| Revenues | 18.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 18.2M |
| Operating Expense | 37.8M |
| Operating I/L | -19.6M |
| Other Income/Expense | 3.0M |
| Interest Income | 2.9M |
| Pretax | -16.6M |
| Income Tax Expense | 15.0M |
| Net Income/Loss | -31.7M |
Repare Therapeutics Inc. is a clinical-stage precision oncology company operating in Canada and the United States. The company utilizes its proprietary SNIPRx platform, which integrates CRISPR technology, to systematically discover and develop targeted cancer therapies focusing on genomic instability and DNA damage repair. Its lead product candidate, RP-3500, is an oral small molecule inhibitor designed for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. Additionally, the company is developing RP-6306, currently in Phase I clinical trial, and a Polymerase Theta program, both targeting genetic alterations associated with various tumors. Repare Therapeutics Inc. generates revenue through the development and potential commercialization of its precision oncology therapeutics.
